Interferon α interferes with immunological tolerance

OncoImmunology

Volumn 2, Issue 12, 2013, Pages

  Becker, Christian ^a   Bopp, Tobias ^a   Steinbrink, Kerstin ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

cAMP; Cancer; IFN alpha; NK cells; PDE; Regulatory T cells; Tolerance

Indexed keywords

ADENYLATE CYCLASE; ALPHA INTERFERON; CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE 1; PEPTIDE VACCINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE IIIB; PHOSPHODIESTERASE IVB; PHOSPHODIESTERASE IVD; PROTEIN KINASE ZAP 70; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

AMINO ACID SYNTHESIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL LEVEL; CELL PROLIFERATION; CYTOKINE RELEASE; CYTOTOXICITY; DNA METHYLATION; DRUG MECHANISM; EFFECTOR CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INACTIVATION; GENE LOCUS; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; MYOSITIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SJOEGREN SYNDROME; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR IMMUNITY; VIRUS INFECTION;

EID: 84894562715     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27528     Document Type: Article

References (10)

1. Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, Bopp T, Zechner U, Merten L, Becker C, et al. Interferon-a suppresses cAMP to disarm human regulatory T cells. Cancer Res 2013; 73:5647-56; PMID:23878189; http:// dx.doi.org/10.1158/0008-5472.CAN-12-3788
2. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Heib V, Becker M, Kubach J, Schmitt S, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007; 204:1303-10; PMID:17502663; http://dx.doi. org/10.1084/jem.20062129
3. Klein M, Vaeth M, Scheel T, Grabbe S, Baumgrass R, Berberich-Siebelt F, Bopp T, Schmitt E, Becker C. Repression of cyclic adenosine monophosphate upregulation disarms and expands human regulatory T cells. J Immunol 2012; 188:1091-7; PMID:22190184; http://dx.doi.org/10.4049/ jimmunol.1102045
4. Huang B, Zhao J, Lei Z, Shen S, Li D, Shen GX, Zhang GM, Feng ZH. miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep 2009; 10:180-5; PMID:19098714; http://dx.doi. org/10.1038/embor.2008.224
5. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007; 445:771-5; PMID:17220874; http://dx.doi.org/10.1038/ nature05543
6. Platanias LC. Mechanisms of type-I- and type-IIinterferon-mediated signalling. Nat Rev Immunol 2005; 5:375-86; PMID:15864272; http://dx.doi. org/10.1038/nri1604
7. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 2007; 178:4820-31; PMID:17404263
8. Petricoin EF 3rd, Ito S, Williams BL, Audet S, Stancato LF, Gamero A, Clouse K, Grimley P, Weiss A, Beeler J, et al. Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling. Nature 1997; 390:629-32; PMID:9403695; http:// dx.doi.org/10.1038/37648
9. Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol 2007; 19:61-6; PMID:17143098; http://dx.doi. org/10.1097/BOR.0b013e328010c547
10. Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, et al. Impaired IFN-a production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012; 72:5188-97; PMID:22836755; http://dx.doi.org/10.1158/0008-5472.CAN-11-3468